The results prove it out. Whether we can go on to a phase 3 or have to do another phase 2 depends on whether the FDA is recalcitrant about using mixed data. With it being equivalent to or much more likely better than Trodelvy without the side effects it would be criminal if the FDA didn't advance it to phase 3.